Akagera Medicines press release
KIGALI, Rwanda, July 20, 2026 — Akagera Medicines, Inc., a clinical-stage biopharmaceutical company developing lipid-nanoparticle therapeutics and vaccines for infectious diseases that disproportionately affect the majority world, together with the TASK Clinical Research Center in South Africa, today announced positive results from the single-ascending-dose (SAD) portion of the first-in-human Phase 1 study of AKG-100, the company’s investigational long-acting intravenous (IV) therapeutic being developed to transform the treatment of TB including drug-resistant TB (DR-TB).
The SAD study evaluated single IV doses of AKG-100 across a range of dose levels in 40 healthy volunteers and 15 patients with pulmonary TB in a 14-day Early Bactericidal Activity (EBA) cohort. AKG-100 was well tolerated at every dose studied, up to and including the highest dose of 850 mg. The overall safety profile was favorable; no participants discontinued due to adverse events and most adverse events were mild and self-limiting.
Read the full press release here.
For more TB updates, check out the TB CAB Weekly Newsletter (Issue #21, 31 July 2026).
The newsletter is brought to you by the Global TB Community Advisory Board (TB CAB) with the support of Treatment Action Group (TAG) and the European AIDS Treatment Group (EATG). Subscribe to the newsletter here.
Source : PRNewswire
Related HIV and Co-Infections News
-
Health Policy Watch: African Union pushes for greater domestic spending on health amid reports of huge disruptions to HIV and TB services
-
WHO releases implementation FAQs to accelerate uptake of new TB diagnostic recommendations
-
[Advocacy brief] TAG: Overcoming barriers to adopting the four-month regimen: A pathfinding mission to improve access to newer TB treatments
Get involved
Are you living with HIV/AIDS? Are you part of a community affected by HIV/AIDS and co-infections? Do you work or volunteer in the field? Are you motivated by our cause and interested to support our work?
Subscribe
Stay in the loop and get all the important EATG updates in your inbox with the EATG newsletter. The HIV & co-infections bulletin is your source of handpicked news from the field arriving regularly to your inbox.